Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Impax Laboratories Inc (NASDAQ:IPXL)

31.52
BATS BZX Real-Time Price
As of 3:12pm ET
 +0.08 / +0.25%
Today’s Change
27.62
Today|||52-Week Range
50.62
-26.29%
Year-to-Date
Whta's in Store for Endocyte (ECYT) this Earnings Season?
11:40am / Zacks.com - Paid Partner Content
4 Low P/CF Stocks to Improve Your Value Investing
Jul 22 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close31.44
Today’s open31.40
Day’s range30.81 - 31.70
Volume14,714
Average volume (3 months)622,881
Market cap$2.3B
Dividend yield--
Data as of 3:12pm ET, 07/28/2016

Growth & Valuation

Earnings growth (last year)-33.33%
Earnings growth (this year)+22.05%
Earnings growth (next 5 years)+16.30%
Revenue growth (last year)+44.36%
P/E ratio65.3
Price/Sales3.58
Price/Book2.15

Competitors

 Today’s
change
Today’s
% change
RAREUltragenyx Pharmaceu...-0.55-0.90%
GLPGGalapagos NV+0.97+1.78%
MDCOMedicines Co+0.99+2.61%
IRWDIronwood Pharmaceuti...-0.17-1.16%
Data as of 3:16pm ET, 07/28/2016

Financials

Last reporting dateJuly 26, 2016
EPS forecast (this quarter)$0.33
Annual revenue (last year)$860.5M
Annual profit (last year)$39.0M
Net profit margin4.53%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
George Frederick Wilkinson
Senior Vice President-
Global Operations
Andrew Schaschl
Corporate headquarters
Hayward, California

Forecasts

Partner Offers

Search for Jobs